While this study reveals that treatment of an obese, insulin-resistant rodent with the antidiabetic drug, ROSI, reverses aberrant BMAL1 recruitment in spite of continued HF feeding, subsequent studies analyzing the effects of alternative insulin sensitizing agents should be performed. This evidence concerns the gene BMAL1 and hydrops fetalis.